Virpax Pharmaceuticals, Inc. (VRPX) Income Statement
VRPX 2024 at a glance
Fiscal year ended December 31, 2024 · U.S. dollarsVRPX revenue and net income
VRPX growth rates
to 2024| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VRPX quarterly EPS vs estimates
Virpax Pharmaceuticals beat the analyst EPS estimate in 3 of the last 8 quarters.
VRPX income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $5.8M | $5.1M | $10.8M | $4.8M | $1.3M | $622,741 | $1.1M |
| Sales, general & admin | $6.3M | $7.8M | $11.1M | $7.2M | $2.9M | $2.6M | $1.5M |
| Total operating expenses | $12.1M | $15.2M | $21.8M | $12.0M | $4.2M | $3.2M | $2.6M |
| Operating income | −$12.1M | −$12.9M | −$21.8M | −$12.0M | −$4.2M | −$3.2M | −$2.6M |
| Interest expense | $103,750 | — | $194,413 | $92,822 | $147,934 | $124,644 | $14,976 |
| Income before taxes | −$12.1M | −$15.2M | −$21.7M | −$12.1M | −$4.3M | −$3.3M | −$2.6M |
| Income taxes | — | −$12,939 | −$194,413 | $92,822 | $147,934 | $124,644 | −$161,141 |
| Net income | −$12.1M | −$15.2M | −$21.5M | −$12.1M | −$4.5M | −$3.4M | −$2.6M |
| EBITDA | −$12.0M | −$2.2M | −$3.3M | $62,260 | $4,000 | −$3.2M | −$2.6M |
| EPS (diluted) | −$44.75 | −$402.01 | −$288.20 | −$61.37 | −$2.50 | −$1.07 | −$0.27 |
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.1M | $1.1M | $2.0M | $1.6M | $1.1M | $1.5M | $1.3M | $1.2M | $1.4M | $2.8M | $3.3M | $3.3M |
| Sales, general & admin | $2.3M | $780,958 | $1.5M | $1.7M | $4.8M | $4.6M | $1.9M | $415,451 | $1.7M | $4.9M | $2.6M | $1.8M |
| Total operating expenses | $3.4M | $1.9M | $3.5M | $3.3M | $4.7M | $6.1M | $3.2M | $1.7M | $3.1M | $7.7M | $5.9M | $5.1M |
| Operating income | −$3.4M | −$1.9M | −$3.5M | −$3.3M | −$4.7M | −$6.1M | −$3.2M | −$1.7M | −$3.1M | −$7.7M | −$5.9M | −$5.1M |
| Interest expense | $0 | $92,748 | $11,000 | — | $130,531 | $0 | $0 | $130,531 | $114,970 | $73,252 | $19,374 | $13,183 |
| Income before taxes | −$3.4M | −$2.0M | −$3.5M | −$3.2M | −$4.6M | −$6.0M | −$3.1M | −$1.5M | −$3.0M | −$7.6M | −$5.9M | −$5.1M |
| Income taxes | — | — | −$3.5M | −$3.3M | −$918 | −$6,115 | −$3,005 | −$130,531 | −$114,970 | −$73,252 | −$19,374 | $13,183 |
| Net income | −$3.4M | −$2.0M | −$3.5M | −$3.2M | −$4.6M | −$6.0M | −$3.1M | −$1.4M | −$2.9M | −$7.6M | −$5.9M | −$5.2M |
| EBITDA | −$3.4M | $10,646 | $19,128 | −$3.3M | −$5.0M | −$6.1M | $126,720 | $1.2M | −$1.9M | −$7.6M | −$5.9M | −$5.1M |
| EPS (diluted) | $12.50 | −$10.75 | −$43.75 | −$2.75 | −$301.50 | −$0.51 | −$67.50 | −$32.50 | −$0.26 | −$162.50 | −$125.00 | −$0.44 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VRPX's financial statements (latest annual report filed March 3, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VRPX financial results
Virpax Pharmaceuticals reported no revenue in fiscal year 2024 (ended December 31, 2024). It had a net loss of $12.1 million. Diluted earnings per share came to −$44.75.
See the VRPX stock overview for the latest quote and news, or the VRPX chart for price history and technical indicators.
VRPX income statement FAQ
Does Virpax Pharmaceuticals have revenue?
Virpax Pharmaceuticals reported no revenue for fiscal year 2024, which ended on December 31, 2024.
Is Virpax Pharmaceuticals profitable?
No. Virpax Pharmaceuticals reported a net loss of $12.1 million in fiscal 2024.
How much does Virpax Pharmaceuticals spend on research and development?
Virpax Pharmaceuticals spent $5.8 million on research and development in fiscal 2024.
What are Virpax Pharmaceuticals's earnings per share?
Virpax Pharmaceuticals earned $-44.75 per diluted share in fiscal 2024, compared with $-402.01 a year earlier.
When does Virpax Pharmaceuticals's fiscal year end?
Virpax Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2024 and was filed on March 3, 2025.